Alexander Kotsinas

A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.

Delta Projects AB offers targeted and intelligent advertising solutions since 2002. Media agencies and companies uses our systems to buy, plan and optimize online display advertising. Our offers are based on real customer data which allows us to deliver solutions and outcomes like noone else. Thanks to our large reach we can reach basically any consumer we want for the advertiser whenever we need to. An advertiser can either direct its advertising against a certain Profile, it can be someone that is more than average interested in Travel for instance. Or they might want to increase sales/leads. Our unique evaluation and payment model is highly appreciated by some of the largest brands in Europe.

Liquid global equity long/short mandate with European bias. Fundamental research in industries we know well combined with a top down directional view. Generate stock picking alpha by actively taking long and short positions in all major industry verticals. Portfolio's leverage and directional exposure derived and adjusted according to our market view. Based in Stockholm.

Fingerprint Cards AB (FPC) is a global biometrics leader, offering intelligent edge to cloud biometrics. We envision a secure, seamless world where you are the key to everything. Our solutions – trusted by enterprises, fintechs, and OEMs – power hundreds of millions of products, enabling billions of secure, convenient authentications daily across devices, cards, and digital platforms. From consumer electronics to cybersecurity and enterprise, our cloud-based identity management platforms support multiple biometric modalities, including fingerprints, iris, facial, and more. With improved security and user experience, we are driving the world to passwordless At FPC, we are serious about security for our users and have been leading development and standardization in this field for over 20 years, ensuring that whatever we do is scalable and works for multiple customers across all platforms. Our technology consists of biometric sensors, processors, modules, software and algorithms that can be used, separately or in combination with each other, in a wide variety of use cases – from mobile and enterprise security to payments and smart homes. We are also driving change in how our identities are used and stored in the cloud, from capturing biometrics in the intelligent edge through to secure storage, on-device or in the cloud, delivering a seamless and secure user experience in activities such as help desk authentication, self-service password recovery, biometric multi-factor authentication (MFA), shared devices and passwordless login. Find out more at: https://www.fpc.com/ Fingerprint Cards AB (publ) is listed on Nasdaq Stockholm (FING B). Our headquarters are in Gothenburg, Sweden.

A new generation of vaccines within animal health We develop vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.

Vivesto is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Vivesto’s proprietary drug delivery platform ™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Vivesto’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: VIVE). To find out more about Vivesto please visit https://www.vivesto.com/en/.

NXT2B is a fully privately owned venture capital company. We are able to make fast decisions on any investment opportunities since we do not require any external capital. The NXT2B team has proven experience in commercialization of innovative projects. NXT2B is a leading venture capital company by partnering with competent and ambitious entrepreneurs; focusing on growth equity investments in healthcare, medical devices and specialty pharmaceutical companies. We make investments and long term commitment in early phase projects of high scientific quality with reasonable business opportunities. NXTB also invests in technology and consumer companies with unique ideas. NXT2B always offers support to its portfolio company management teams to build market leading companies. NXT2B believes in active ownership and will work with the companies to develop them.